CLINICAL TRIALS PROFILE FOR LIXIVAPTAN

Clinical Trials for Lixivaptan

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00578695 ↗	THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation	Completed	Biogen	Phase 3	The purpose of this study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in patients with congestive heart failure.
NCT00578695 ↗	THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation	Completed	Cardiokine Biopharma, LLC	Phase 3	The purpose of this study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in patients with congestive heart failure.
NCT00578695 ↗	THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation	Completed	CardioKine Inc.	Phase 3	The purpose of this study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in patients with congestive heart failure.
NCT00660959 ↗	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia	Completed	Biogen	Phase 3	The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIADH.
NCT00660959 ↗	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia	Completed	Cardiokine Biopharma, LLC	Phase 3	The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIADH.
NCT00660959 ↗	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia	Completed	CardioKine Inc.	Phase 3	The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIADH.

Clinical Trial Conditions for Lixivaptan

Condition Name

Condition Name for
Intervention	Trials
Polycystic Kidney Disease, Adult	3
Congestive Heart Failure	1
Euvolemic Hyponatremia	1
Healthy	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Polycystic Kidney Diseases	5
Kidney Diseases	5
Hyponatremia	4
Polycystic Kidney, Autosomal Dominant	4

Clinical Trial Locations for Lixivaptan

Trials by Country

Trials by Country for
Location	Trials
United States	118
India	22
Russian Federation	4
Argentina	4
Poland	4

Trials by US State

Trials by US State for
Location	Trials
California	6
Pennsylvania	6
Illinois	5
Florida	5
Alabama	5

Clinical Trial Progress for Lixivaptan

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	6
Recruiting	2
Withdrawn	1

Clinical Trial Sponsors for Lixivaptan

Sponsor Name

Sponsor Name for
Sponsor	Trials
Cardiokine Biopharma, LLC	6
CardioKine Inc.	6
Biogen	5

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	22